Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin with Metformin

Launched by CELLTRION · Aug 23, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment for adults with Type 2 diabetes (T2DM) who are not achieving good blood sugar control with their current medications, Metformin and Empagliflozin. The treatment being studied is called Pioglitazone, and the trial aims to find out if adding this medication can help improve blood sugar levels safely. This is a Phase 3 study, which means it is one of the final stages of testing before the treatment can potentially be approved for general use.

To participate in this trial, you need to be an adult diagnosed with Type 2 diabetes and willing to sign a consent form to join the study. However, if you have another type of diabetes, a history of severe allergic reactions to diabetes medications, or serious uncontrolled complications from diabetes, you won't be eligible. If you do join, you can expect regular check-ups and monitoring to see how well the new treatment works for you. This trial is currently recruiting participants, so it's a great opportunity for those looking for additional support in managing their diabetes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults at the time of signing the Informed Consent Form (ICF)
• • Signed the written ICF voluntarily after being fully informed of the objectives, methods, and effects of the study
• • Diagnosed with T2DM
• Exclusion Criteria:
• • Diagnosed with other types of diabetes than T2DM
• • History of hypersensitivity reaction to the components or drugs of the same class as the IP or the background therapy
• • Uncontrolled severe complications of diabetes